Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 25, 2025
Emerging Company Profile
Lifordi: Applying ADCs to autoimmune conditions
With $70M series A, biotech backed by Arch, 5am and Atlas is developing a targeted steroid it believes will be safer, with lower and less frequent dosing
BioCentury | May 23, 2024
Product Development
Hummingbird’s dual ADC payloads deliver one-two punch to tumors
Singapore biotech aiming to overcome drug resistance by creating therapies carrying multiple payloads with orthogonal MoAs
BioCentury | Jun 1, 2023
Data Byte
The next-generation checkpoint pipeline expands, slowly
The majority of T cell checkpoint targets tracked by BioCentury continue to see new entrants to the pipeline
BioCentury | Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | May 18, 2021
Finance
Novo ventures into Asia with Hummingbird’s series C round
The investment signals more to come for Novo’s new Singapore office
BioCentury | Mar 26, 2021
Product Development
Next-generation checkpoint development surges as rare wins overshadow setbacks
Companies look to overcome challenges in next-generation checkpoints with new targets and modalities
BioCentury | Feb 1, 2020
Distillery Therapeutics
Agonizing the checkpoint protein VISTA for systemic and cutaneous lupus
BioCentury | Dec 6, 2019
Targets & Mechanisms
A view of immune reprogramming from ASH
ASH abstracts reveal new mechanisms and consequences of immune cell repolarization in hematology
BioCentury | Oct 19, 2019
Product Development
Tracking the rise and fall of next-generation checkpoint targets for cancer
BioCentury’s analysis of next-generation checkpoint targets finds three that are gathering steam
BioCentury | Sep 16, 2019
Company News
Amgen taps Hummingbird’s tech for epitope-based antibody selection
Items per page:
1 - 10 of 28